Rapid advances in glomerular disease, from single-cell tech to biomarkers and phase 3 trials, are reshaping diagnosis and treatment.
Back
The Changing Landscape of Glomerular Disease Research and Treatment
Barbara Gillespie, MD, and Tobias Huber, MD, discuss the rapidly evolving landscape of glomerular disease research and care. They cover recent scientific advances, from biomarker discovery and molecular technologies to emerging targeted therapies, that are reshaping the understanding and treatment of conditions such as APOL1-mediated kidney disease, membranous nephropathy, and IgA nephropathy. The discussion also highlights global collaborative efforts, including initiatives to refine clinical trial endpoints and accelerate therapeutic development, offering practicing clinicians insight into the breakthroughs and challenges shaping the future of glomerular medicine.
The Changing Landscape of Glomerular Disease Research and Treatment
Episodes
All
All
APOL1 kidney disease highlights the need for community trust, increased screening, and stronger clinical trial participation.
Anti-nephrin autoantibodies are redefining minimal change disease and enabling more precise, steroid-sparing treatment strategies.
PLA2R antibodies are advancing precision care in membranous nephropathy and informing new surrogate endpoints through PARASOL.
The PARASOL initiative is reshaping glomerular disease trials through shared data and improved surrogate endpoints.
Experts outline a 2026 vision for glomerular disease care, including new endpoints, combination therapies, and gene therapy advances.
Advertisement
Advertisement
Trending on HCPLive
1
Omalizumab-Facilitated OIT Enables Maintenance Dosing in Food Allergy
2
Phase 3 Dermatomyositis Trial Sees Brepocitinib Meet Primary Endpoint
3
After Sickle Cell Gene Therapy, What Comes Next?
4
Tirzepatide Demonstrates Cardioprotective Effects in T2D With ASCVD
5